Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

Fig. 1

The overall least-squares (LS) mean change from baseline in monthly MHDs is shown for patients with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The monthly LS mean changes in monthly MHDs for patients receiving these treatments is shown in the bottom row for patients with LFEM and with HFEM. ***p ≤ .001, **p ≤ .01, *p ≤ .05 vs placebo

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us